Deals of the Year 2024: Malin buyback gives shareholders a 25% boost in value
Back
A buyback by Malin Corporation of over 40% of its issued share capital, at a premium of over 25% on its latest share price, represented a substantial ongoing commitment to returning excess capital to shareholders.
Malin is a publicly listed company trading on the Euronext Growth Market of Dublin. It invests in life sciences companies, with a primary focus on oncology, immunology and genetic diseases. Following the sale of its remaining shareholding in Nasdaq-listed biotechnology firm Immunocore, Malin undertook a €140 million share buyback.

The offer, which completed in March 2023, was done at a price of €9.30 per ordinary share. This represented a premium of a....

 

To continue, please log in


 
 
 
Forgot your password?
 
The Latest Issue
September 2024 Issue of Finance Dublin

Order a subscription to Finance Dublin

Take out a subscription - I would like to take out a subscription, enabling me to gain immediate access to the site and this month's edition. For details on pricing options and subscription benefits please click here.

Without your explicit permission FinanceDublin.com will never share any of your information (including your e-mail address). Your information is collected in accordance with our Privacy Policy.

If you have any questions, please contact us.

This article appeared in the May 2024 edition.